Lyobeads, or lyophilised spheres, are a game-changer in freeze-drying for diagnostics and pharma R&D. They offer unmatched flexibility, allowing a single formulation to adapt to various applications. This versatility translates to significant cost and time savings, making lyobeads a popular choice for diagnostic companies in particular.
Biopharma Group, a leader in lyobead processing innovation, offers the LyobeadPRO™, a revolutionary device designed to produce the highest quality lyobeads - up to 7,000 beads per hour - with unmatched precision and consistency.
Why choose the LyobeadPRO™?
Dispensing accuracy is paramount in diagnostics, impacting technical accuracy, patient safety, regulatory compliance, and resource efficiency. The LyobeadPRO™ delivers precise dosing with finely adjustable controls, ensuring consistent material volume in every bead. Additionally, consistent results are crucial for reliable diagnostics and R&D. The LyobeadPRO™ creates replicable bead size and volume, that eliminates variability to enhance the reliability of your tests and experiments.
As a benchtop lyobead generation instrument, the LyobeadPRO™ caters to both R&D and small-batch production needs. Its adaptability allows you to use it for initial formulation testing, scale-up activities, through to mid-scale production. Its compact design simplifies integration into your laboratory environment without sacrificing valuable space, and empowers you to achieve precise bead size adjustments, a critical factor for specific applications. This level of control optimises your lyophilisation process for maximum efficiency.
The LyobeadPRO™ advantage:
- High-quality, accurate bead production
- Fine dosing control
- Versatility
- Compact design
- Fast reconstitution rates
- Repeatability and consistency
The LyobeadPRO™ is a user-friendly tool that empowers you to achieve precision and consistency in lyobead production. Contact Biopharma Group today to learn more about how the LyobeadPRO™ can revolutionise your diagnostics and pharma R&D processes.